Innovative mRNA modulating strategies are creating fresh opportunities for tackling hard-to-drug diseases.
In this webinar, experts Dr. Timur Samatov and Dr. Xavier Maréchal demonstrate how Evotec’s high-throughput RT-qPCR and ScreenSeq™ transcriptomics platforms drive these mRNA focused approaches – delivering rapid, scalable, and multidimensional insights.
Join us to see how a fully transcriptomics enabled workflow can advance mRNA driven discovery and speed progression from screening to candidate nomination.
What You’ll Learn:
- Explore why mRNA modulating strategies are expanding therapeutic possibilities
- See how high-throughput, multiplexed RT-qPCR enables rapid screening of up to 13,000 compounds per day
- Discover how unbiased, multidimensional transcriptomics accelerates hit validation, hit expansion, and SAR – perfectly complementing RT-qPCR data
Presenters
Group Leader, Transcriptomics
Evotec
Dr. Timur Samatov, is a molecular biologist with a groundbreaking academic background. Getting his PhD from Moscow State University in 2006, he developed a pioneering cell-free genetic display technology. His postdoctoral work at the Max Planck Institute for Biophysical Chemistry focused on pre-mRNA splicing, where he developed high-throughput assays and conducted large-scale screens for splicing inhibitors.
Research Scientist, High Throughput Screening and Biology
Evotec
Dr. Xavier Maréchal is a biochemist specializing in enzymology and RT‑qPCR. He earned his PhD from the University Pierre et Marie Curie in Paris in 2011. Xavier joined Evotec in 2018, where he further specialized in the design and optimization of RT‑qPCR‑based HTS approaches for the identification of gene expression and mRNA splicing modulators. He now serves as a Team Leader within the High Throughput Screening and Biology department.
Production Partner
Evotec
Evotec is a global leader in drug discovery and development, offering extensive CRO and CDMO services across all stages of the R&D continuum, from target identification to the clinic, delivering efficient, high-quality, and cost-effective solutions. We integrate deep disease understanding, a multimodality approach, advanced technologies and tailored solutions to enhance the probability of success. Our innovative and flexible approach supports collaboration through standalone CRO/CDMO services, integrated drug discovery and development programs, or strategic partnerships, regardless of your stage in the discovery-development journey.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.